Literature DB >> 8001003

Urinary system.

C F Lynch1, M B Cohen.   

Abstract

BACKGROUND: Although site-specific cancer frequencies and incidence rates for the United States are regularly reported by the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) program, they have not been reported by histologic type within a specific site. This report presents data for 76,303 cancers of the urinary tract by histologic type.
METHODS: Cancer data were obtained from the SEER program. Urinary tract cancers were eligible if they were histologically confirmed, in situ or invasive, and diagnosed between 1973 and 1987. The urinary tract was divided into the following sites: kidney and renal pelvis, ureter, urinary bladder, urethra, and other urinary. Histologic types were evaluated by site, age, sex, race, incidence, and survival.
RESULTS: Of the 76,303 cancers, 72.0% were transitional cell carcinomas and 22.0% were adenocarcinomas. Adenocarcinoma was the most common histologic type in the kidney and renal pelvis (also referred to as renal cell carcinoma), whereas transitional cell carcinoma was the most common histologic type in the remainder of the urinary tract. For the more common histologic types, age-adjusted incidence rates were always higher among males than females.
CONCLUSIONS: Because adenocarcinomas represent most kidney and renal pelvis cancers and transitional cell carcinomas represent most urinary bladder cancers, these histologic types largely explain incidence and survival trends reported for these two common cancer sites. Future population-based cancer epidemiologic studies should try to focus more on specific histologic types within a cancer site to better clarify risk factors and incidence and survival trends for cancer.

Entities:  

Mesh:

Year:  1995        PMID: 8001003     DOI: 10.1002/1097-0142(19950101)75:1+<316::aid-cncr2820751314>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  41 in total

1.  Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy.

Authors:  Thomas F Chromecki; Julian Mauermann; Eugene K Cha; Robert S Svatek; Harun Fajkovic; Pierre I Karakiewicz; Yair Lotan; Derya Tilki; Patrick J Bastian; Bjoern G Volkmer; Francesco Montorsi; Wassim Kassouf; Giacomo Novara; Hans-Martin Fritsche; Vincenzo Ficarra; Christian G Stief; Colin P Dinney; Eila Skinner; Karl Pummer; Yves Fradet; Shahrokh F Shariat
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

Review 2.  Chemoprevention of bladder cancer.

Authors:  Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

3.  Loss of FOXA1 Drives Sexually Dimorphic Changes in Urothelial Differentiation and Is an Independent Predictor of Poor Prognosis in Bladder Cancer.

Authors:  Opal L Reddy; Justin M Cates; Lan L Gellert; Henry S Crist; Zhaohai Yang; Hironobu Yamashita; John A Taylor; Joseph A Smith; Sam S Chang; Michael S Cookson; Chaochen You; Daniel A Barocas; Magdalena M Grabowska; Fei Ye; Xue-Ru Wu; Yajun Yi; Robert J Matusik; Klaus H Kaestner; Peter E Clark; David J DeGraff
Journal:  Am J Pathol       Date:  2015-05       Impact factor: 4.307

4.  Squamous cell carcinoma of the suprapubic cystostomy tract with bladder involvement.

Authors:  Jae Min Chung; Jeong Hyun Oh; Su Hwan Kang; Seong Choi
Journal:  Korean J Urol       Date:  2013-09-10

5.  Urinary bladder cancer in yemen.

Authors:  Abdullah Saleh Al-Samawi; Saleh Mansoor Aulaqi
Journal:  Oman Med J       Date:  2013-09

6.  Understanding the development of human bladder cancer by using a whole-organ genomic mapping strategy.

Authors:  Tadeusz Majewski; Sangkyou Lee; Joon Jeong; Dong-Sup Yoon; Andrzej Kram; Mi-Sook Kim; Tomasz Tuziak; Jolanta Bondaruk; Sooyong Lee; Weon-Seo Park; Kuang S Tang; Woonbok Chung; Lanlan Shen; Saira S Ahmed; Dennis A Johnston; H Barton Grossman; Colin P Dinney; Jain-Hua Zhou; R Alan Harris; Carrie Snyder; Slawomir Filipek; Steven A Narod; Patrice Watson; Henry T Lynch; Adi Gazdar; Menashe Bar-Eli; Xifeng F Wu; David J McConkey; Keith Baggerly; Jean-Pierre Issa; William F Benedict; Steven E Scherer; Bogdan Czerniak
Journal:  Lab Invest       Date:  2008-05-05       Impact factor: 5.662

7.  Chemoprevention in bladder cancer: What's new?

Authors:  Jean-Baptiste Lattouf
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

8.  Histologic variants of urothelial bladder cancer and nonurothelial histology in bladder cancer.

Authors:  Venu Chalasani; Joseph L Chin; Jonathan I Izawa
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

9.  Incidence analyses of bladder cancer in the Nile delta region of Egypt.

Authors:  Stacey A Fedewa; Amr S Soliman; Kadry Ismail; Ahmed Hablas; Ibrahim A Seifeldin; Mohamed Ramadan; Hoda G Omar; Jerome Nriagu; Mark L Wilson
Journal:  Cancer Epidemiol       Date:  2009-09-16       Impact factor: 2.984

10.  Impact of age and gender on the clinicopathological characteristics of bladder cancer.

Authors:  Parag Gupta; Manoj Jain; Rakesh Kapoor; K Muruganandham; Aneesh Srivastava; Anil Mandhani
Journal:  Indian J Urol       Date:  2009-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.